Steve Seedhouse
analystMale0.0Global Dominance: 0.00%
Steve Seedhouse is an analyst at Cantor Fitzgerald, who has compared AbCellera to Genentech, emphasizing its potential to become a significant player in the biotech industry, particularly with its innovative drug pipeline.
Power0
Reach0
Collect
Not in the pool (under ¢1).
Recent news mentions
Steve Seedhouse is a Cantor Fitzgerald analyst who commented on the trial results.
AbCellera stock soars on ‘off the chart’ trial results from hot flash treatment for menopausal womenThe Globe and Mail·
Canada· 2026-08-10
Canada· 2026-08-10
Steve Seedhouse is an analyst at Cantor Fitzgerald, referring to AbCellera as potentially Canada’s Genentech.
Has Canada’s biotech moment finally arrived?The Globe and Mail·Canada· 2026-08-04
Canada· 2026-08-04
